TY - JOUR
T1 - Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19
AU - Sechenov StopCOVID Research Team
AU - Munblit, Daniel
AU - Bobkova, Polina
AU - Spiridonova, Ekaterina
AU - Shikhaleva, Anastasia
AU - Gamirova, Aysylu
AU - Blyuss, Oleg
AU - Nekliudov, Nikita
AU - Bugaeva, Polina
AU - Andreeva, Margarita
AU - DunnGalvin, Audrey
AU - Comberiati, Pasquale
AU - Apfelbacher, Christian
AU - Genuneit, Jon
AU - Avdeev, Sergey
AU - Kapustina, Valentina
AU - Guekht, Alla
AU - Fomin, Victor
AU - Svistunov, Andrey A.
AU - Timashev, Peter
AU - Subbot, Vladislav S.
AU - Royuk, Valery V.
AU - Drake, Thomas M.
AU - Hanson, Sarah Wulf
AU - Merson, Laura
AU - Carson, Gail
AU - Horby, Peter
AU - Sigfrid, Louise
AU - Scott, Janet T.
AU - Semple, Malcolm G.
AU - Warner, John O.
AU - Vos, Theo
AU - Olliaro, Piero
AU - Glybochko, Petr
AU - Butnaru, Denis
AU - Abdeeva, Elina
AU - Alekseeva, Nikol
AU - Antsiferova, Elena
AU - Artigas, Elena
AU - Bairashevskaia, Anastasiia
AU - Belkina, Anna
AU - Bezrukov, Vadim
AU - Bordyugov, Semyon
AU - Bratukhina, Maria
AU - Chen, Jessica
AU - Deunezhewa, Salima
AU - Elifkhanova, Khalisa
AU - Ezhova, Anastasia
AU - Filippova, Yulia
AU - Frolova, Aleksandra
AU - Ganieva, Julia
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/9
Y1 - 2021/9
N2 - Background: The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. Results: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions: Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
AB - Background: The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. Results: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions: Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
KW - asthma
KW - COVID-19
KW - long COVID
KW - PASC
KW - post-COVID Condition
KW - post-COVID Syndrome
KW - postacute sequelae SARS-CoV-2 infection
KW - risk factors
UR - https://www.scopus.com/pages/publications/85113152948
U2 - 10.1111/cea.13997
DO - 10.1111/cea.13997
M3 - Article
C2 - 34351016
AN - SCOPUS:85113152948
SN - 0954-7894
VL - 51
SP - 1107
EP - 1120
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 9
ER -